# Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

> **NCT00777101** · PHASE2 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 233 (actual)

## Conditions studied

- Advanced Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Neratinib
- **DRUG:** Lapatinib
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00777101
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-04
- **Primary completion:** 2011-03
- **Final completion:** 2018-06-03
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777101, "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00777101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*